Abstract
Peliosis hepatis is characterized by hepatic sinusoidal dilatation and multiple blood-filled cystic cavities within the liver parenchyma. It can be due to infectious diseases, immunological disorders, neoplasia, and the use of various kinds of drugs. We presented the case of a nonsmoker 55-year-old man who complained about a 5-month history of arthritis. Medical history was consistent with psoriasis and hypertension. He denied any drug use or alcohol consumption. Physical examination showed extended psoriatic lesions. He had arthritis of the knees, ankles, wrists, and elbows. His body mass index was 22 kg/m2. Laboratory findings revealed an increased serum gamma-glutamyl transferase level (1014 UI/L, normal value (N) 11–55) and total alkaline phosphatase (278 U/L, N 30–171). Hepatitis A, B, and C serologic test results were negative. Anti-nuclear antibodies, anti-Ro/SSA, anti-GP210, anti-SP100, anti-SLA, anti-LKM1, anti-M2, anti-LC1, and anti-PML were also negative. Histopathological examination of a liver biopsy specimen revealed peliosis hepatis.
The pelvic radiograph showed bilateral ankylosis of sacroiliac joints. Hand and foot radiographs showed periosteal bone apposition. The diagnosis of psoriatic arthritis associated with peliosis hepatis was made. The patient received infliximab (5 mg/kg) with a significant improvement after 3 months of follow-up. Peliosis hepatis should be considered as a possible etiology of liver enzyme abnormalities in patients with psoriatic arthritis. We highlighted the effectiveness and safety of the TNF inhibitors in the treatment of peliosis hepatis associated with psoriatic arthritis.
Key Points • Peliosis hepatis should be considered as a possible etiology of liver enzyme disturbance in patients with psoriatic arthritis. • Special caution should be advised in the management of psoriatic arthritis associated with peliosis hepatis to avoid the worsening of liver function. • Infliximab is suggested as a possible treatment of peliosis hepatis associated with psoriatic arthritis. |
Similar content being viewed by others
References
Biswas S, Rolain JM (2010) Bartonella infection: treatment and drug resistance. Future Microbiol 5(11):1719–1731. https://doi.org/10.2217/fmb.10.133
Zak FG (1950) Peliosis hepatis. Am J Pathol 26(1):1–15
Crocetti D, Palmieri A, Pedullà G, Pasta V, D’Orazi V, Grazi GL (2015) Peliosis hepatis: personal experience and literature review. World J Gastroenterol 21(46):13188–13194. https://doi.org/10.3748/wjg.v21.i46.13188
Lachaux A, Bertrand Y, Bouvier R, Dumont C, Pinzaru M, Hermier M (1996) Intravenous immunoglobulin therapy in an infant with autoimmune hemolytic anemia associated with necrotic hepatitis and peliosis. J Pediatr Gastroenterol Nutr 22(1):99–102. https://doi.org/10.1097/00005176-199601000-00016
Kim SB et al (2015) Peliosis hepatis presenting with massive hepatomegaly in a patient with idiopathic thrombocytopenic purpura. Clin Mol Hepatol 21(4):387–392. https://doi.org/10.3350/cmh.2015.21.4.387
Cordeiro RA, Hoff LS, Garcia MVF, LeãoFilho HM, Borba EF (2018) Peliosis hepatis and systemic lupus erythematosus: a rare condition identified by magnetic resonance imaging. Rev Assoc Med Bras (1992) 64(1):19–21. https://doi.org/10.1590/1806-9282.64.01.19
Matsumoto T, Yoshimine T, Shimouchi K, Shiotu H, Kuwabara N, Fukuda Y, Hoshi T (1992) The liver in systemic lupus erythematosus: pathologic analysis of 52 cases and review of Japanese autopsy registry data. Hum Pathol 23(10):1151–1158. https://doi.org/10.1016/0046-8177(92)90033-Y
Nesher G, Dollberg L, Zimran A, Hershko C (1985) Hepatosplenic peliosis after danazol and glucocorticoids for ITP. N Engl J Med 312(4):242–243. https://doi.org/10.1056/nejm198501243120413
Izumi S, Nishiuchi M, Kameda Y, Nagano S, Fukunishi T, Kohro T, Shinji Y (1994) Laparoscopic study of peliosis hepatis and nodular transformation of the liver before and after renal transplantation: natural history and aetiology in follow-up cases. J Hepatol 20(1):129–137. https://doi.org/10.1016/s0168-8278(05)80479-9
Adler M et al (1987) Hepatic vascular disease after kidney transplantation: report of two cases and review of the literature. Nephrol Dial Transplant 2(3):183–188. https://doi.org/10.1093/oxfordjournals.ndt.a091534
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665–2673. https://doi.org/10.1002/art.21972
Schoels MM, Aletaha D, Alasti F, Smolen JS (2015) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75(5):811–818. https://doi.org/10.1136/annrheumdis-2015-207507
Choi SK et al (2009) Spontaneous liver rupture in a patient with peliosis hepatis: a case report. World J Gastroenterol 15(43):5493–5497. https://doi.org/10.3748/wjg.15.5493
Gouya H, Vignaux O, Legmann P, de Pigneux G, Bonnin A (2001) Peliosis hepatis: triphasic helical CT and dynamic MRI findings. Abdom Imaging 26(5):507–509. https://doi.org/10.1007/s00261-001-0023-x
Wang SY, Ruggles S, Vade A, Newman BM, Borge MA (2001) Hepatic rupture caused by peliosis hepatis. J Pediatr Surg 36:1456–1459. https://doi.org/10.1053/jpsu.2001.26397
Charatcharoenwitthaya P, Tanwandee T (2014) Education and imaging: hepatobiliary and pancreatic: spontaneous intrahepatic hemorrhage from peliosis hepatis-an uncommon complication of a rare liver disorder. J Gastroenterol Hepatol 29(10):1754–1754. https://doi.org/10.1111/jgh.12636
Yoshida M, Utsunomiya D, Takada S, Komohara Y, Mizoshiri T, Oda S, Harada K, Ikeda O (2020) The imaging findings of peliosis hepatis on gadoxetic acid enhanced MRI. Radiol Case Rep 15(8):1261–1265. https://doi.org/10.1016/j.radcr.2020.04.059
Yu CY, Chang LC, Chen LW, Lee TS, Chien RN, Hsieh MF, Chiang KC et al (2014) Peliosis hepatis complicated by portal hypertension following renal transplantation. World J Gastroenterol 20(9):2420–2425. https://doi.org/10.3748/wjg.v20.i9.2420
Pan W, Hong HJ, Chen YL, Han SH, Zheng CY (2013) Surgical treatment of a patient with peliosis hepatis: a case report. World J Gastroenterol 19(16):2578–2582. https://doi.org/10.3748/wjg.v19.i16.2578
Sanz-Canalejas L, Gómez-Mampaso E, Cantón-Moreno R, Varona-Crespo C, Fortún J, Dronda F (2014) Peliosis hepatis due to disseminated tuberculosis in a patient with AIDS. Infection 42:185–189. https://doi.org/10.1007/s15010-013-0490-3
Corpa MV, Bacchi MM, Bacchi CE, Coelho KI (2004) Peliosis hepatis associated with lymphoplasmacytic lymphoma: an autopsy case report. Arch Pathol Lab Med 128(11):1283–1285
Kleger A, Bommer M, Kunze M, Klaus J, Leithaeuser F, Wegener M, Adler G, Dikopoulos N (2009) First reported case of disease : peliosis hepatis as cardinal symptom of Hodgkin’s lymphoma. Oncologist 14(11):1088–1094
Creamer D, Jagger R, Allen M, Bicknell R, Barker J (1997) Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 137(6):851–855. https://doi.org/10.1046/j.1365-2133.1997.19772089.x
Bedair TM, ElNaggar MA, Joung YK, Han DK (2017) Recent advances to accelerate re-endothelialization for vascular stents. J Tissue Eng 8:1–14. https://doi.org/10.1177/2041731417731546
Vignaux O, Legmann P, de Pinieux G, Chaussade S, Spaulding C, Couturier D, Bonnin A (1999) Hemorrhagic necrosis due to peliosis hepatis: imaging findings and pathological correlation. Eur Radiol 9(3):454–456. https://doi.org/10.1007/s003300050691
Schoenlank FW (1916) Ein fall von peliosis hepatis. Virchows Arch Pathol Anat Physiol Klin Med 222:358–364
Acknowledgements
We would like to thank Dr. Noureddine LITAIEM for language editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Slouma, M., Khrifech, Y., Dhahri, R. et al. Psoriatic arthritis associated with peliosis hepatis: characteristics and therapeutic management. Clin Rheumatol 40, 3827–3832 (2021). https://doi.org/10.1007/s10067-021-05647-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-021-05647-1